Koey
2021-06-17
Great
Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology<blockquote>Midatech Pharma凭借“突破性”给药技术飙升</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":168025329,"tweetId":"168025329","gmtCreate":1623944737961,"gmtModify":1631890645433,"author":{"id":3555258134444739,"idStr":"3555258134444739","authorId":3555258134444739,"authorIdStr":"3555258134444739","name":"Koey","avatar":"https://static.tigerbbs.com/b00aea8cc65a7b91263ae19adeaa9eee","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Great </p></body></html>","htmlText":"<html><head></head><body><p>Great </p></body></html>","text":"Great","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/168025329","repostId":1199020816,"repostType":4,"repost":{"id":"1199020816","kind":"news","pubTimestamp":1623940823,"share":"https://www.laohu8.com/m/news/1199020816?lang=zh_CN&edition=full","pubTime":"2021-06-17 22:40","market":"us","language":"en","title":"Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology<blockquote>Midatech Pharma凭借“突破性”给药技术飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199020816","media":"thestreet","summary":"Midatech Pharma (MTP) shares soared Thursday after the U.K.-based biotechnology company announced a","content":"<p>Midatech Pharma (<b>MTP</b>) shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p><p><blockquote>Midatech制药（<b>MTP</b>）周四，这家总部位于英国的生物技术公司宣布其专业技术的开发取得“突破”，该技术可以将蛋白质形成长效注射药物疗法，随后该公司股价飙升。</blockquote></p><p> Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p><p><blockquote>Midatech Pharma的美国存托凭证在纳斯达克上涨52.46%，至3.11美元，此前该公司表示，体外数据显示其Q-Sphera技术具有将蛋白质配制为长效注射产品的潜力。</blockquote></p><p> Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p><p><blockquote>Q-Sphera是一种采用专有3D打印技术将药物封装在微球中的技术，微球可以注射在体内形成储库，在一周到几个月的可预测的持续时间内释放药物。</blockquote></p><p> How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p><p><blockquote>生物科技股如何飞得这么高，估值如何？如果您正在考虑投资生物技术股票，请观看此视频以更好地了解复杂的行业。体积90%</blockquote></p><p> “A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p><p><blockquote>该公司在一份声明中表示：“大量最新一代药物都是基于蛋白质的，重新配制为长效注射剂可以为患者、医生和付款人带来显着的好处。”他补充说，这一结果是迄今为止没有其他商业或学术组织能够成功复制。</blockquote></p><p> “The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p><p><blockquote>Midatech表示：“该公司相信，没有其他商业或学术组织能够使用能够商业规模的方法长期成功提供治疗性蛋白质。”他指出，2020年全球单克隆抗体制剂（mAb）的销售额为1540亿美元。</blockquote></p><p> The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p><p><blockquote>这家也在伦敦AIM市场上市的英国生物技术公司表示，下一步将进一步优化包封单克隆抗体的载药量和溶出曲线。</blockquote></p><p> Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p><p><blockquote>除其他进展外，该公司还开始与MTD211的潜在许可合作伙伴进行讨论，MTD211是一种治疗精神分裂症的药物，以Rexulti品牌销售。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Midatech Pharma Soars on 'Breakthrough' Drug Delivery Technology<blockquote>Midatech Pharma凭借“突破性”给药技术飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMidatech Pharma Soars on 'Breakthrough' Drug Delivery Technology<blockquote>Midatech Pharma凭借“突破性”给药技术飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">thestreet</strong><span class=\"h-time small\">2021-06-17 22:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Midatech Pharma (<b>MTP</b>) shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.</p><p><blockquote>Midatech制药（<b>MTP</b>）周四，这家总部位于英国的生物技术公司宣布其专业技术的开发取得“突破”，该技术可以将蛋白质形成长效注射药物疗法，随后该公司股价飙升。</blockquote></p><p> Midatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.</p><p><blockquote>Midatech Pharma的美国存托凭证在纳斯达克上涨52.46%，至3.11美元，此前该公司表示，体外数据显示其Q-Sphera技术具有将蛋白质配制为长效注射产品的潜力。</blockquote></p><p> Q-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.</p><p><blockquote>Q-Sphera是一种采用专有3D打印技术将药物封装在微球中的技术，微球可以注射在体内形成储库，在一周到几个月的可预测的持续时间内释放药物。</blockquote></p><p> How Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%</p><p><blockquote>生物科技股如何飞得这么高，估值如何？如果您正在考虑投资生物技术股票，请观看此视频以更好地了解复杂的行业。体积90%</blockquote></p><p> “A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.</p><p><blockquote>该公司在一份声明中表示：“大量最新一代药物都是基于蛋白质的，重新配制为长效注射剂可以为患者、医生和付款人带来显着的好处。”他补充说，这一结果是迄今为止没有其他商业或学术组织能够成功复制。</blockquote></p><p> “The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.</p><p><blockquote>Midatech表示：“该公司相信，没有其他商业或学术组织能够使用能够商业规模的方法长期成功提供治疗性蛋白质。”他指出，2020年全球单克隆抗体制剂（mAb）的销售额为1540亿美元。</blockquote></p><p> The U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.</p><p><blockquote>这家也在伦敦AIM市场上市的英国生物技术公司表示，下一步将进一步优化包封单克隆抗体的载药量和溶出曲线。</blockquote></p><p> Among other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.</p><p><blockquote>除其他进展外，该公司还开始与MTD211的潜在许可合作伙伴进行讨论，MTD211是一种治疗精神分裂症的药物，以Rexulti品牌销售。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology\">thestreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/investing/midatech-pharma-mtp-stock-drug-delivery-technology","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199020816","content_text":"Midatech Pharma (MTP) shares soared Thursday after the U.K.-based biotechnology company announced a \"breakthrough\" in the development of its specialized technology that can form proteins into long-lasting injectable drug therapies.\nMidatech Pharma's American depositary receipts were up 52.46% at $3.11 on the Nasdaq after the company said that in-vitro data show the potential of its Q-Sphera technology to formulate proteins into long-acting injectable products.\nQ-Sphera is a technology that employs proprietary 3D printing techniques to encapsulate drugs in microspheres which may be injected to form depots in the body that release the drug over predictable, sustained periods from one week to several months.\nHow Do Biotech Stocks Fly So High and How Are They Valued?If you're considering investing in biotech stocks, watch this video to get a better understanding of a complicated sector.Volume 90%\n“A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,\" the company said in a statement, adding that the results are a “breakthrough” that to date no other commercial or academic organization has been able to successfully replicate.\n“The company believes no other commercial or academic organization has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling,” Midatech said, noting that sales of monoclonal antibody formulations, or mAbs,were $154 billion globally in 2020.\nThe U.K. biotechnology company, which also is listed on London's AIM market, said its next steps will be to further optimize the drug loading and dissolution profile for encapsulated monoclonal antibodies.\nAmong other developments, the company also has begun discussions with potential licensing partners for MTD211, a treatment for schizophrenia marketed under the brand name Rexulti.","news_type":1,"symbols_score_info":{"MTP":0.9}},"isVote":1,"tweetType":1,"viewCount":1229,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/168025329"}
精彩评论